(Q48158821)

9 February 2018

title

Lamotrigine in typical absence epilepsy (English)

1 reference

9 February 2018

1 reference

S Buoni

1

1 reference

9 February 2018

S Grosso

series ordinal

2

1 reference

9 February 2018

A Fois

series ordinal

3

1 reference

9 February 2018

publication date

1 July 1999

1 reference

9 February 2018

published in

Brain and Development

1 reference

9 February 2018

volume

21

1 reference

9 February 2018

issue

5

1 reference

9 February 2018

page(s)

303-306

1 reference

9 February 2018

Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

Mechanisms of action of new antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

Controlled trial of lamotrigine (Lamictal) for treatment-resistant partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

Controlled trial of lamotrigine (Lamictal) for refractory partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

Lamotrigine treatment in childhood drug resistant epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

Lamotrigine for generalised epilepsies

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

Lamotrigine as an add-on drug in typical absence seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

Lamotrigine in the treatment of absence seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

Lamotrigine in primary generalised epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

Lamotrigine in treatment of 120 children with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

Toxic epidermal necrolysis after treatment with lamotrigine (Lamictal)

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

Suspected lamotrigine-induced toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2899%2900023-6

7 January 2021

10.1016/S0387-7604(99)00023-6

Identifiers

DOI

1 reference

9 February 2018

release_5j6zibgz6rc7tfaqg5ur3rfmdm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5j6zibgz6rc7tfaqg5ur3rfmdm

24 November 2022

mapped directly with Wikidata item

1 reference

9 February 2018